↓ Skip to main content

Personalised Medicine

Overview of attention for book
Attention for Chapter 12: Regenerative Medicine: Advances from Developmental to Degenerative Diseases
Altmetric Badge

Mentioned by

facebook
1 Facebook page

Citations

dimensions_citation
3 Dimensions

Readers on

mendeley
17 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Regenerative Medicine: Advances from Developmental to Degenerative Diseases
Chapter number 12
Book title
Personalised Medicine
Published in
Advances in experimental medicine and biology, January 2017
DOI 10.1007/978-3-319-60733-7_12
Pubmed ID
Book ISBNs
978-3-31-960731-3, 978-3-31-960733-7
Authors

Nicholas F. Blair, Thomas J. R. Frith, Ivana Barbaric

Abstract

Chronic tissue and organ failure caused by an injury, disease, ageing or congenital defects represents some of the most complex therapeutic challenges and poses a significant financial healthcare burden. Regenerative medicine strategies aim to fulfil the unmet clinical need by restoring the normal tissue function either through stimulating the endogenous tissue repair or by using transplantation strategies to replace the missing or defective cells. Stem cells represent an essential pillar of regenerative medicine efforts as they provide a source of progenitors or differentiated cells for use in cell replacement therapies. Whilst significant leaps have been made in controlling the stem cell fates and differentiating them to cell types of interest, transitioning bespoke cellular products from an academic environment to off-the-shelf clinical treatments brings about a whole new set of challenges which encompass manufacturing, regulatory and funding issues. Notwithstanding the need to resolve such issues before cell replacement therapies can benefit global healthcare, mounting progress in the field has highlighted regenerative medicine as a realistic prospect for treating some of the previously incurable conditions.

Mendeley readers

The data shown below were compiled from readership statistics for 17 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 17 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 6 35%
Researcher 3 18%
Student > Ph. D. Student 2 12%
Student > Master 2 12%
Student > Doctoral Student 1 6%
Other 1 6%
Unknown 2 12%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 5 29%
Pharmacology, Toxicology and Pharmaceutical Science 2 12%
Agricultural and Biological Sciences 2 12%
Medicine and Dentistry 2 12%
Psychology 1 6%
Other 3 18%
Unknown 2 12%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 September 2017.
All research outputs
#10,397,729
of 11,727,438 outputs
Outputs from Advances in experimental medicine and biology
#2,245
of 3,113 outputs
Outputs of similar age
#222,813
of 263,906 outputs
Outputs of similar age from Advances in experimental medicine and biology
#2
of 3 outputs
Altmetric has tracked 11,727,438 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,113 research outputs from this source. They receive a mean Attention Score of 3.3. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 263,906 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 3 others from the same source and published within six weeks on either side of this one.